BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Isconova to Present Matrix-M™ Adjuvant at Modern Vaccines Adjuvants & Delivery Systems Conference


6/29/2012 10:29:09 AM

Uppsala, July 29, 2012 -- Isconova AB (NASDAQ OMX First North: ISCO) will give a scientific presentation on Thursday 5th July, at 11:30 CET at Modern Vaccines Adjuvants & Delivery Systems – MVADS Conference (Copenhagen, July 4-6).

The development of novel generations of vaccines and therapies reinforces the need for development of new potent and safe adjuvants and delivery systems. Linda Stertman, PhD and R&D Director at Isconova, will present on Isconova’s proprietary adjuvant technology Matrix-M™ in preclinical studies and clinical trials. For more information about the conference program, please visit www.meetingsmanagement.co.uk.

About Isconova

Isconova AB is a leading international vaccine adjuvant company. Isconova has vast knowledge of vaccine systems and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconovas nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2005. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix M™. Isconova’s partners include J&J/Crucell, Pfizer, Merck & Co., The Jenner Institute and Genocea. The Company is headquartered in Uppsala, Sweden.

Isconova is listed on NASDAQ OMX First North (ticker: ISCO)

www.isconova.com

Contact:

Andrea Gottfridson

(+46) 18 16 17 13

abisco@isconova.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES